Assessment of ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia due to Streptococcus pneumoniae: insights from two randomized trials.

MedStar author(s):
Citation: Diagnostic Microbiology & Infectious Disease. 75(3):298-303, 2013 Mar.PMID: 23357290Institution: MedStar Washington Hospital CenterDepartment: Medicine/Pulmonary-Critical CareForm of publication: Journal ArticleMedline article type(s): Clinical Trial, Phase III | Journal Article | Multicenter Study | Randomized Controlled Trial | Research Support, Non-U.S. Gov'tSubject headings: *Anti-Bacterial Agents/tu [Therapeutic Use] | *Cephalosporins/tu [Therapeutic Use] | *Community-Acquired Infections/dt [Drug Therapy] | *Pneumonia, Pneumococcal/dt [Drug Therapy] | Aged | Aged, 80 and over | Bacteremia/dt [Drug Therapy] | Bacteremia/mi [Microbiology] | Ceftriaxone/tu [Therapeutic Use] | Community-Acquired Infections/mi [Microbiology] | Female | Humans | Logistic Models | Male | Microbial Sensitivity Tests | Middle Aged | Odds Ratio | Pneumonia, Pneumococcal/mi [Microbiology] | Retrospective Studies | Treatment OutcomeYear: 2013ISSN:
  • 0732-8893
Name of journal: Diagnostic microbiology and infectious diseaseAbstract: Ceftaroline fosamil resulted in higher cure rates than ceftriaxone in patients with community-acquired bacterial pneumonia in 2 randomized trials (FOCUS 1 and FOCUS 2). The present analysis examines the subgroup of patients with Streptococcus pneumoniae infection to determine whether the apparent difference in cure rates persists after adjusting for potential covariates. We retrospectively pooled subjects with S. pneumoniae isolated at baseline in the original studies and employed logistic regression to evaluate the independent relationship between clinical cure and treatment with ceftaroline. Covariates evaluated included demographics, severity of illness, bacteremia, and pathogen characteristics. The final cohort included 139 subjects (69 ceftaroline, 70 ceftriaxone). Unadjusted cure rates were 85.5% and 68.6% (P = 0.009) in the ceftaroline and ceftriaxone groups, respectively. After logistic regression, ceftaroline remained associated with higher cure rates. Our findings indicate that ceftaroline may result in improved outcomes of S. pneumoniae pneumonia. Formal clinical trials are warranted to confirm this hypothesis. Copyright 2013 Elsevier Inc. All rights reserved.All authors: Eckburg PB, Friedland HD, Kollef M, Llorens L, Shorr AFFiscal year: FY2013Digital Object Identifier: Date added to catalog: 2013-09-17
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 23357290 Available 23357290

Ceftaroline fosamil resulted in higher cure rates than ceftriaxone in patients with community-acquired bacterial pneumonia in 2 randomized trials (FOCUS 1 and FOCUS 2). The present analysis examines the subgroup of patients with Streptococcus pneumoniae infection to determine whether the apparent difference in cure rates persists after adjusting for potential covariates. We retrospectively pooled subjects with S. pneumoniae isolated at baseline in the original studies and employed logistic regression to evaluate the independent relationship between clinical cure and treatment with ceftaroline. Covariates evaluated included demographics, severity of illness, bacteremia, and pathogen characteristics. The final cohort included 139 subjects (69 ceftaroline, 70 ceftriaxone). Unadjusted cure rates were 85.5% and 68.6% (P = 0.009) in the ceftaroline and ceftriaxone groups, respectively. After logistic regression, ceftaroline remained associated with higher cure rates. Our findings indicate that ceftaroline may result in improved outcomes of S. pneumoniae pneumonia. Formal clinical trials are warranted to confirm this hypothesis. Copyright 2013 Elsevier Inc. All rights reserved.

English

Powered by Koha